BridgeBio reports Q3 2026 loss of $0.42 per share, revenue $353M and strong Attruby growth
BridgeBio Pharma posted a third‑quarter loss of $0.42 per share, beating analysts' expectations. Revenue came in at $353.17 million, well above forecasts. U.S. Attruby net product revenue rose 14% sequentially to $253.2 million, and the company ended the quarter with about $1.5 billion in cash. Management reaffirmed a $4 billion peak‑year sales target for Attruby and highlighted upcoming FDA decisions, including a November 27, 2026 action date for BBP‑418.
Why it matters
UBS kept a Buy rating and a $92.00 price target, citing the strong Attruby sales and narrowed loss (source). The cash balance is described as sufficient to fund upcoming product launches and pipeline milestones (source).
Key facts
- 1Q3 loss was $0.42 per share, beating estimates by $0.18. finance.yahoo.com
- 2Revenue was $353.17 million, exceeding forecasts by $61.96 million. quiverquant.com
- 3U.S. Attruby net product revenue was $253.2 million, up about 14% quarter‑on‑quarter and 134% year‑over‑year. finance.yahoo.com
- 4Cash, cash equivalents and marketable securities totaled about $1.5 billion at quarter end. quiverquant.com
- 5Management expects Attruby to meet or exceed a $4 billion peak‑year sales assumption. tipranks.com
- 6BBP‑418 has an FDA action date of November 27, 2026. tipranks.com
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.